Sugi Predict

Sugi Predict / Compounds / SCHEMBL1260935

SCHEMBL1260935

SCHEMBL1260935

CCOC(=O)c1c(C)ccnc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ MAPT P10636 3/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ NUDT1 P36639 1/20 0.42
▸ NR1H2 P55055 1/20 0.42
▸ NR1H3 Q13133 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ KDM4E B2RXH2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30503143 1.00 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL2578343 0.87 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL15729552 0.85 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL844466 0.84 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL31214389 0.83 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL306569 0.83 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL14352047 0.83 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL2113012 0.83 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL15729551 0.83 LMNA (0.45) CA12CA1CA2CA7CA9
SCHEMBL21496638 0.83 CA12 (0.44) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069571-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA PLC (GB) 2026-03-12 — — US disclosed
US-20260042780-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC (US) 2026-02-12 — — US disclosed
EP-4688754-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 — — US disclosed
EP-4426688-B1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA LTD (GB) 2025-12-03 — — EP disclosed
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 — — US disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 — — EP disclosed
WO-2024211744-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 — — US disclosed
CN-118201918-A DDR1 and DDR2 inhibitors for the treatment of cancer and fibrotic diseases 莱德克斯制药公共有限公司 2024-06-14 — — CN disclosed
US-5627138-A HERBICIDES SANDOZ LTD. (CH) 1997-05-06 — — US disclosed
US-5627137-A HERBICIDES SANDOZ LTD. (CH) 1997-05-06 — — US disclosed
US-5561101-A HERBICIDES SANDOZ LTD. (CH) 1996-10-01 — — US disclosed
EP-0714393-A1 THIAZOLES AS ANTIVIRAL PFIZER INC. (US) 1996-06-05 — — EP disclosed
US-5506192-A HERBICIDES SANDOZ LTD. 1996-04-09 — — US disclosed
WO-1995005378-A1 ANTIVIRAL THIAZOLES PFIZER INC. (US) 1995-02-23 — — WO disclosed
US-4652572-A HISTAMINE H2-ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1987-03-24 — — US disclosed
US-4547512-A HISTAMINE H2-ANTAGONIST SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-10-15 — — US disclosed
US-4439437-A 2-[2-Thiazolyl or 2-guanidino-4-thiazolyl methylthioethyl(or butyl)amino]-3-(hydroxy or carboxy)pyridines, compositions containing same and method of use SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1984-03-27 — — US disclosed
EP-0065825-A1 Pyridine derivatives as histamine H2 antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1982-12-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CD CA12 2633/4885CA1 3461/4885CA2 832/4885
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF GRIN2C, HCN1, KCNC1 CA12 1734/4885CA1 1154/4885CA2 704/4885
US-20260042780-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PTEN, PIK3C2A, PIK3CA CA12 1630/4885CA1 1604/4885CA2 146/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 CA12 2698/4885CA1 1962/4885CA2 4123/4885
US-20260069571-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES DDR1, DDR2, TGFBR2 CA12 4329/4885CA1 4815/4885CA2 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.